Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial
Open label RCT in patients with HIV given tuberculosis treatment (n=460) did not confirm non-inferiority of raltegravir 400 mg bd vs efavirenz 600 mg daily (both in combination with tenofovir and lamivudine) for virological suppression at week 48 (61% vs 66%).
Source:
The Lancet Infectious Diseases
SPS commentary:
A related commentary notes that the results of this study were unanticipated, however it is imperative that treatment of HIV-associated tuberculosis is based on data from definitive clinical trials. Rifampicin is unlikely to be replaced by another drug in the near future, thus efavirenz in combination with two nucleoside reverse transcriptase inhibitors remains the ART regimen best supported by data for use in patients with tuberculosis.